Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2003

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in double-blind conditions to a treatment with subcutaneous low molecular weight heparin (nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy or up to a maximum of 4 months (+/- 10 days).
Epistemonikos ID: b220e3ae41f79abb448f31c88cd1dd0513974db6
First added on: Mar 14, 2016